publication . Article . 2016

Effect of YangZheng XiaoJi Extract, DME-25, on endothelial cells and their response to Avastin.

Owen, Sioned; Gao, Y.; Zhi, X.; Wei, C.; Wu, Y.; Jiang, Wen Guo;
Open Access English
  • Published: 01 Mar 2016
  • Publisher: International Institute of Anticancer Research
  • Country: United Kingdom
Abstract
ackground: Angiogenesis is a cellular process that has been identified as a key target for therapy in solid cancer. However, over the course of anti-angiogenic therapies, cancer cells acquire resistance to these therapies after an initial period of success. DME-25 is an extract from Yang Zheng Xiao Ji, a traditional Chinese medicine that has been reported to benefit patients with cancer by alleviating chemotherapy-associated symptoms and possibly inhibiting key cancer cell traits. This study aimed to explore if DME-25 on its own and in combination with avastin affected endothelial cell behaviour in vitro in the presence of hypoxic lung cancer-conditioned medium ...
Subjects
Medical Subject Headings: genetic structureseye diseases
free text keywords: RC0254
Related Organizations
22 references, page 1 of 2

1 Cancer Research UK. http://www.cancerresearchuk.org/healthprofessional/lung-cancer-statistics.

2 Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P and Grossi F: Targeting the VEGF pathway: antiangiogenic strategies in the treatment of nonsmall cell lung cancer. Crit Rev Oncol Hematol 68: 183-196, 2008. [OpenAIRE]

3 Luoto KR, Kumareswaran R and Bristow RG: Tumor hypoxia as a driving force in genetic instability. Genome Integr 4: 5, 2013. [OpenAIRE]

4 Vaupel P and Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl 5): 4-9, 2004.

5 Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC and Yoon SS: Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1alpha. Int J Cancer 132: 29-41, 2013. [OpenAIRE]

6 Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH and Melillo G: Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8: 1867- 1877, 2009. [OpenAIRE]

7 Kondoh M, Ohga N, Akiyama K, Hida Y, Maishi N, Towfik AM, Inoue N, Shindoh M and Hida K: Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment. PLoS One 8: e80349, 2013.

8 Zhang S, Gu CH, Gao, XD and Wu YL: A random, doubleblinded and multicentre study of chemotherapy assisted Yangzhengxiaoji capsule on treating primary hepatic carcinoma. Chinese Journal of Difficult and Complicated Cases 8: 461-464, 2009.

9 Li Sun JR, Yei Tan and Xuedong Gao: Yang capsule in treatment of hepatocellular carcinoma with interventional chemotherapy random double-blind, multicenter clinical study. World Chinese Journal 8: 688-691, 2013.

10 Ligan Xing XZ, Guixin Li, Xiqin Zhang, Xindong Sun, Qishen Guo and Jinming Yu: Controlled clinical studies in the effects of Yang capsule in advanced lung cancer in combination with chemotherapy. Chinese Journal of Cancer Prevention and Treatment 21: 384-386, 2014.

11 Xingjun Cui WM and Xuejie Bi: Effect of Yangzhengxiaoji Capsule on cellular immune function in patients with advanced gastric cancer chemotherapy. Chinese Journal of Difficult and Complicated Cases 10: 703-704, 2011.

12 Xue Kan SF and Ji Jiafu: Meta-anlaysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis. Chinese Journal Clinical Oncology 40: 1318- 1323, 2013.

13 Ye L, Ji K, Frewer N, Ji J and Jiang WG: Impact of Yangzheng Xiaoji on the adhesion and migration of human cancer cells: the role of the AKT signalling pathway. Anticancer Res 32: 2537- 2543, 2012. [OpenAIRE]

14 Jiang WG, Ye L, Ruge F, Sun PH, Sanders AJ, Ji K, Lane J, Zhang L, Satherley L, Weeks HP, Zhi X, Gao Y, Wei C, Wu Y and Mason MD: Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth. Anticancer Res 35: 1321-1331, 2015. [OpenAIRE]

15 Jiang WG, Ye L, Ji K, Ruge F, Wu Y, Gao Y, Ji J and Mason MD: Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role of focal adhesion kinase signalling. Oncol Rep 30: 1405-1413, 2013.

22 references, page 1 of 2
Abstract
ackground: Angiogenesis is a cellular process that has been identified as a key target for therapy in solid cancer. However, over the course of anti-angiogenic therapies, cancer cells acquire resistance to these therapies after an initial period of success. DME-25 is an extract from Yang Zheng Xiao Ji, a traditional Chinese medicine that has been reported to benefit patients with cancer by alleviating chemotherapy-associated symptoms and possibly inhibiting key cancer cell traits. This study aimed to explore if DME-25 on its own and in combination with avastin affected endothelial cell behaviour in vitro in the presence of hypoxic lung cancer-conditioned medium ...
Subjects
Medical Subject Headings: genetic structureseye diseases
free text keywords: RC0254
Related Organizations
22 references, page 1 of 2

1 Cancer Research UK. http://www.cancerresearchuk.org/healthprofessional/lung-cancer-statistics.

2 Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P and Grossi F: Targeting the VEGF pathway: antiangiogenic strategies in the treatment of nonsmall cell lung cancer. Crit Rev Oncol Hematol 68: 183-196, 2008. [OpenAIRE]

3 Luoto KR, Kumareswaran R and Bristow RG: Tumor hypoxia as a driving force in genetic instability. Genome Integr 4: 5, 2013. [OpenAIRE]

4 Vaupel P and Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl 5): 4-9, 2004.

5 Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC and Yoon SS: Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1alpha. Int J Cancer 132: 29-41, 2013. [OpenAIRE]

6 Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH and Melillo G: Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8: 1867- 1877, 2009. [OpenAIRE]

7 Kondoh M, Ohga N, Akiyama K, Hida Y, Maishi N, Towfik AM, Inoue N, Shindoh M and Hida K: Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment. PLoS One 8: e80349, 2013.

8 Zhang S, Gu CH, Gao, XD and Wu YL: A random, doubleblinded and multicentre study of chemotherapy assisted Yangzhengxiaoji capsule on treating primary hepatic carcinoma. Chinese Journal of Difficult and Complicated Cases 8: 461-464, 2009.

9 Li Sun JR, Yei Tan and Xuedong Gao: Yang capsule in treatment of hepatocellular carcinoma with interventional chemotherapy random double-blind, multicenter clinical study. World Chinese Journal 8: 688-691, 2013.

10 Ligan Xing XZ, Guixin Li, Xiqin Zhang, Xindong Sun, Qishen Guo and Jinming Yu: Controlled clinical studies in the effects of Yang capsule in advanced lung cancer in combination with chemotherapy. Chinese Journal of Cancer Prevention and Treatment 21: 384-386, 2014.

11 Xingjun Cui WM and Xuejie Bi: Effect of Yangzhengxiaoji Capsule on cellular immune function in patients with advanced gastric cancer chemotherapy. Chinese Journal of Difficult and Complicated Cases 10: 703-704, 2011.

12 Xue Kan SF and Ji Jiafu: Meta-anlaysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis. Chinese Journal Clinical Oncology 40: 1318- 1323, 2013.

13 Ye L, Ji K, Frewer N, Ji J and Jiang WG: Impact of Yangzheng Xiaoji on the adhesion and migration of human cancer cells: the role of the AKT signalling pathway. Anticancer Res 32: 2537- 2543, 2012. [OpenAIRE]

14 Jiang WG, Ye L, Ruge F, Sun PH, Sanders AJ, Ji K, Lane J, Zhang L, Satherley L, Weeks HP, Zhi X, Gao Y, Wei C, Wu Y and Mason MD: Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth. Anticancer Res 35: 1321-1331, 2015. [OpenAIRE]

15 Jiang WG, Ye L, Ji K, Ruge F, Wu Y, Gao Y, Ji J and Mason MD: Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role of focal adhesion kinase signalling. Oncol Rep 30: 1405-1413, 2013.

22 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue